Idecabtagene Vicleucel
‘Reassuring’ study shows no link between CAR T-cell therapy and secondary cancers
A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.
Serious cardiovascular events rare after CAR T-cell therapy
A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.
Risk for second primary malignancies no greater with CAR-T than other standard therapies
Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.
FDA approves earlier use of Abecma for triple-class exposed multiple myeloma
The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.
FDA requires boxed safety warning for all CAR T-cell therapies
The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.
FDA official says CAR-T ‘incredibly beneficial’ despite secondary malignancy risk
Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.
VIDEO: Updated KarMMa-3 results demonstrate safety of idecabtagene vicleucel
Healio spoke with Chakra Chaulagain, MD, about updated safety results from the KarMMa-3 trial presented at ASH 2023.
FDA issues warning about risk of T-cell malignancies after CAR T-cell therapy
The FDA published a safety advisory on the risk of T-cell malignancies among individuals receiving autologous chimeric antigen receptor T-cell therapy for the treatment of certain blood cancers.
CAR-T outcomes for multiple myeloma similar regardless of race, ethnicity
Black, Hispanic and white individuals treated with idecabtagene vicleucel for relapsed or refractory multiple myeloma experienced similar PFS and OS, according to study results published in Blood Advances.
Immunotherapies ‘offer incredible hope’ in journey toward multiple myeloma cure
Although multiple myeloma remains incurable, treatment advances during the past several years have dramatically improved clinicians’ ability to slow progression of the disease.